Welcome to our dedicated page for eXoZymes news (Ticker: EXOZ), a resource for investors and traders seeking the latest updates and insights on eXoZymes stock.
eXoZymes Inc. develops AI-enhanced enzymes and a cell-free biomanufacturing platform for producing high-value natural products from abundant feedstock. Company news centers on exozymes, enzyme cascades operating outside living cells, and the use of the platform in nutraceuticals, novel medicines, active pharmaceutical ingredients, biofuels, food flavors, cosmetics, and valuable chemicals.
Recurring updates cover N-trans-caffeoyltyramine, or NCT, NCTx commercialization activity, pilot-scale production and technology-transfer work, partner validation, strategic focus on pharmaceutical and nutraceutical markets, accelerator participation, investor presentations, and periodic operating results communications.
eXoZymes (EXOZ) has entered a commercial-scale manufacturing agreement with Curia Global to advance production of its NCT product, with program activities expected to begin in the fourth quarter of 2026.
Under the agreement, eXoZymes will transfer its proprietary NCT manufacturing process to Curia, which will scale it at facilities in León, Spain, and Rozzano, Italy. The work covers cross validation of enzyme fermentation, cell-free reaction and purification steps, alongside process modeling and engineering analysis, to define a technical roadmap for larger-scale and potential commercial manufacturing of NCT in 2027.
eXoZymes (NASDAQ:EXOZ) announced second quarter 2026 results and a business update, alongside an investor webinar scheduled for 5:00 PM ET on August 20, 2026. The company highlighted major progress in its lead NCT program, financing activities, and a new government grant.
eXoZymes reported that its optimized NCT process achieved a 10-fold increase in manufacturing productivity versus pilot scale, producing approximately 67% more NCT per liter while cutting reaction time by over 80%, advancing the program beyond original commercial economic targets. The company completed a June underwritten public offering generating about $6 million in gross proceeds, and secured an approximately $2 million two-year Phase IIB SBIR grant from the NIH to advance preclinical development of novel cannabinoid analogs.
Operating expenses for Q2 2026 were $2.95 million, up from $2.55 million in Q2 2025. Net loss was $2.88 million for the quarter and $5.25 million for the first half of 2026. eXoZymes ended the quarter with $5.65 million in cash and cash equivalents, which it expects will fund operations through year-end 2026.
eXoZymes (NASDAQ:EXOZ) reported significant optimization of its manufacturing process for N‑trans‑caffeoyltyramine (NCT), building on a prior 100‑liter pilot run. The updated process delivered about 67% more NCT per liter while reducing reaction time by over 80%, resulting in a tenfold increase in productivity and improved estimated economics for future commercial‑scale production.
According to eXoZymes, internal process‑cost assessments indicate that the estimated manufacturing cost equivalent for NCT has fallen by more than 100x from the first process version to the current optimized one. The company is simplifying and industrializing the process as it prepares for technology transfer to future commercial manufacturing partners.
MDB Capital Holdings (NASDAQ: MDBH) reported operational highlights for the first six months of 2026, including serving as sole bookrunner and underwriter on the $20 million BUDA Juice IPO, joint bookrunner on the $15 million Ticketplus IPO, and completing a $5.9 million public offering for eXoZymes (NASDAQ: EXOZ).
MDB expanded its pipeline of early-stage disruptive companies, advanced discussions with potential MDB Direct/Public Ventures strategic partners, and prepared a spin-out of PatentVest as an independent public company. For the first half of 2026, MDB reported a net loss of approximately $16.1 million, fixed operating expenses of about $5 million, net cash used of about $3 million, and roughly $12.1 million in cash, current assets and marketable securities net of liabilities. Management will host a Zoom webinar on August 13, 2026, at 4:30 p.m. ET.
eXoZymes (NASDAQ:EXOZ) will host a live webinar and conference call on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its second quarter 2026 results. A detailed press release on the quarter will be issued before the call.
CEO Michael Heltzen and select members of the management team will review recent developments, ongoing initiatives and anticipated milestones, followed by a Q&A session. Investors can pre-register for the webinar or access the live event via eXoZymes’ investor relations website.
eXoZymes (NASDAQ: EXOZ) has been selected for the inaugural U.S. Department of Energy Genesis Mission, a nine-month AI initiative uniting national labs, academia and industry. The project totals approximately $747,000 in funding, including about $147,000 awarded to eXoZymes.
eXoZymes will collaborate with Lawrence Berkeley National Laboratory researchers Dr. Edward Baidoo and Dr. Hector Garcia Martin to build AI-powered digital twins for cell-free biomanufacturing. The company will generate curated cell-free enzymatic datasets, while LBNL teams develop metabolomic workflows and hybrid digital twin models that merge enzyme kinetics, reactor physics and machine learning. According to eXoZymes, participation also provides access to the DOE Genesis Mission Platform’s advanced AI models, AI agents and high-performance computing resources.
eXoZymes (NASDAQ:EXOZ) received a $2,028,518 NIH Phase IIB SBIR grant from NIGMS to advance rare cannabinoids and cannabinoid analogs for drug discovery. The two-year, non-dilutive award begins July 1, 2026 and adds a second biosolution to its pipeline alongside NCT.
The program targets advanced enzyme expression systems, expanded analog libraries, and preclinical evaluation of eXoZymes' cannabinoid library. Including this award, total non-dilutive funding to the company and predecessor programs reaches $19.7 million, and includes a sub-award to Dr. Vikram Shende's laboratory at Occidental College.
eXoZymes (NASDAQ:EXOZ) closed a public offering of 330,575 units, including 34,440 from partial over-allotment exercise. Each unit includes two common shares and one warrant. The offering priced shares at $8.99 and warrants at $0.02, for gross proceeds of about $5.95 million.
Warrants become exercisable in one year at $11.24 per share, last five years, and are unlisted. According to eXoZymes, net proceeds will fund NCT development, additional products, R&D, working capital, and general corporate purposes.
eXoZymes (NASDAQ:EXOZ) priced a public offering of units at $18.00 per unit, each containing two common shares and one warrant. The company sold 592,270 shares and 296,135 warrants, for expected gross proceeds of about $5.33 million before expenses.
The underwriter has a 45-day option for up to 44,420 additional units. Warrants have a $11.24 exercise price, a five-year term, reset and redemption features, and will not be listed. Proceeds will support NCT-related development, R&D, and general corporate purposes.
eXoZymes (NASDAQ:EXOZ) announced graduation from the Shell GameChanger Accelerator powered by NLR on May 7, 2026. From 2023–2026 the partnership supported advancement of eXoZymes' cell-free biomanufacturing platform toward commercial viability through technical guidance, separations evaluation, and technoeconomic and lifecycle analysis.